Global Nanopharmaceutical Drugs Market - Analysis and Forecast (2018-2026)

Focus on Nanodrugs and its Application in Therapeutics, Competitive Landscape, and Country

Published Year: 2018
SKU: BH00655SA

5000

Online Access for 1-3 Users. Permission to Print.


In case you require a hard copy, there will be an additional charge of $500. Please email us at [email protected] with your request.

A quick peek into the report

Table of Contents

Request a Sample

1 Market Overview

          1.1    What are Nanopharmaceuticals?
          1.2    Historical Trends
          1.3    Comparative Analysis of Conventional Medicine and Nanomedicine
          1.4    Issues and Concerns in Nanotech Product Development and its Commercialization
          1.5    Impact of Market Drivers and Market Restraints
          1.6    Assumptions and Limitations for Market Size Calculations
          1.7    Global Nanopharmaceutical Drugs Market Scenario

2 Market Dynamics

          2.1    Impact Analysis
          2.2    Market Drivers
                   2.2.1    Government Initiative
                   2.2.2    Nanopharmaceuticals: A Hope for Patent Expired Formulations
                   2.2.3    Increase in Number of Abbreviated New Drug Application (ANDA), Biologics License Application (BLA) Approvals: Closing the Gap for Generic Nanomedicines
                   2.2.4    Nanomedicine - Innovative Ways of Treating Challenging Conditions
          2.3    Market Restraints
                   2.3.1    Economic & Financial Barriers
                   2.3.2    Undefined Regulatory Approvals
          2.4    Market Opportunities
                   2.4.1    Pipeline Creating Market Opportunity
                   2.4.2    The Nanomedicine Market: Small Particles – Big Business
          2.5    Market Trends
                   2.5.1    Pfizer, Merck Focusing on Nanomedicine as Next Disruption in Pharma
                   2.5.2    Trends in Approval and Development
                   2.5.3    Publications Trend Scenario

3 Competitive Insights

          3.1    Pipeline Analysis and Market Opportunity
          3.2    Product Launches and Approvals

4 Industry Insights

          4.1    Introduction
          4.2    Patent Analysis
          4.3    Funding Scenario
          4.4    Regulatory Bodies

5 Global Nanopharmaceutical Drug  Market (by Drug Carrier)

          5.1    Liposomes
          5.2    Polymer
          5.3    Nanocrystals
          5.4    Inorganic
          5.5    Protein
          5.6    Others

6 Global Nanopharmaceutical Drugs Market (by Application)

          6.1    Oncology
          6.2    Neurology
          6.3    Anti-inflammatory/Immunology
          6.4    Anti-infective
          6.5    Cardiovascular/Physiology
          6.6    Others

7 Global Nanopharmaceutical Drugs Market (by Distribution Channel)

          7.1    Hospital Pharmacies
          7.2    Retail Pharmacies
          7.3    Online Pharmacies

8 Global Nanopharmaceutical Drugs Market (by Region)

          8.1    North America
                   8.1.1    The U.S.
                   8.1.2    Canada
          8.2    Europe
                   8.2.1    Germany
                   8.2.2    France
                   8.2.3    The U.K.
                   8.2.4    Spain
                   8.2.5    Italy
                   8.2.6    Rest-of-Europe
          8.3    Asia-Pacific
                   8.3.1    China
                   8.3.2    Japan
                   8.3.3    Rest-of-Asia-Pacific
          8.4    Rest-of-the-World

9 Company Profiles

          Overview
          9.1    AbbVie Inc.
                   9.1.1    Company Overview
                   9.1.2    Role of Abbvie Inc. in Nanopharmaceuticals Drug Market
                   9.1.3    Financials
                   9.1.4    Key Insights about Financial Health of the Company
                   9.1.5    Global Presence
                   9.1.6    SWOT Analysis
          9.2    AMAG Pharmaceuticals
                   9.2.1    Company Overview
                   9.2.2    Role of AMAG Pharmaceutical in Global Nanopharmaceutical Drugs Market
                   9.2.3    Financials
                   9.2.4    Key Insights about Financial Health of the Company
                   9.2.5    Global Presence
                   9.2.6    SWOT Analysis
          9.3    Amgen Inc.
                   9.3.1    Company Overview
                   9.3.2    Role of Amgen Inc. in Nanopharmaceuticals Drug Market
                   9.3.3    Financials
                   9.3.4    Key Insights about Financial Health of the Company
                   9.3.5    Global Presence
                   9.3.6    SWOT Analysis
          9.4    Astellas Pharma Inc.
                   9.4.1    Company Overview
                   9.4.2    Role of Astellas Pharma Inc. in Global Nanopharmaceutical Drugs Market
                   9.4.3    Financials
                   9.4.4    Key Insights about Financial Health of the company
                   9.4.5    SWOT Analysis
          9.5    AstraZeneca PLC
                   9.5.1    Company Overview
                   9.5.2    Role of AstraZeneca PLC in Global Nanopharmaceutical Drugs Market
                   9.5.3    Financials
                   9.5.4    Key Insights about Financial Health of the company
                   9.5.5    Global Presence
                   9.5.6    SWOT Analysis
          9.6    CELGENE CORPORATION
                   9.6.1    Company Overview
                   9.6.2    Role of CELGENE CORPORATION in Global Nanopharmaceutical Drugs Market
                   9.6.3    Financials
                   9.6.4    Key Insights about Financial Health of the company
                   9.6.5    Global Presence
                   9.6.6    SWOT Analysis
          9.7    Gilead Sciences, Inc.
                   9.7.1    Company Overview
                   9.7.2    Role of Gilead Sciences, Inc in Global Nanopharmaceutical Drugs Market
                   9.7.3    Financials
                   9.7.4    Key Insights about Financial Health of the company
                   9.7.5    Global Presence
                   9.7.6    SWOT Analysis
          9.8    JOHNSON & JOHNSON
                   9.8.1    Company Overview
                   9.8.2    Role of Johnson & Johnson in Global Nanopharmaceutical Drugs Market
                   9.8.3    Financials
                   9.8.4    Key Insights about Financial Health of the company
                   9.8.5    Global Presence
                   9.8.6    SWOT Analysis
          9.9    Merck & Co., Inc.
                   9.9.1    Company Overview
                   9.9.2    Role of Merck & Co., Inc. in Nanopharmaceutical Drugs Market
                   9.9.3    Financials
                   9.9.4    Key Insights about Financial Health of the company
                   9.9.5    Global Presence
                   9.9.6    SWOT Analysis
         9.10   Novartis AG
                   9.10.1    Company Overview
                   9.10.2    Role of Novartis AG in Nanopharmaceutical Drugs Market
                   9.10.3    Financials
                   9.10.4    Key Insights about Financial Health of the company
                   9.10.5    Global Presence
                   9.10.6    SWOT Analysis
         9.11   Pfizer, Inc.
                   9.11.1    Company Overview
                   9.11.2    Role of Pfizer, Inc. in the Pharmaceutical Drug Market
                   9.11.3    Financials
                   9.11.4    Key Insights on the Financial Health of the Company
                   9.11.5    Global Presence
                   9.11.6    SWOT Analysis
         9.12   Hoffmann-La Roche AG
                   9.12.1    Company Overview
                   9.12.2    Role of F. Hoffmann-La Roche AG in the Nanopharmaceutical Drugs Market
                   9.12.3    Financials
                   9.12.4    Key Insights about Financial Health of the company
                   9.12.5    Global Presence
                   9.12.6    SWOT Analysis
         9.13   Sanofi S.A
                   9.13.1    Company Overview
                   9.13.2    Role of Sanofi S.A in Global Nanopharmaceutical Drugs Market
                   9.13.3    Financials
                   9.13.4    Key Insights about Financial Health of the company
                   9.13.5    Global Presence
                   9.13.6    SWOT Analysis
         9.14   Shire Plc.
                   9.14.1    Company Overview
                   9.14.2    Role of Shire plc. in Global Nanopharmaceutical Drugs Market
                   9.14.3    Financials
                   9.14.4    Key Insights about Financial Health of the company
                   9.14.5    Global Presence
                   9.14.6    SWOT Analysis
         9.15   Teva Pharmaceuticals Industries Limited
                    9.15.1    Company Overview
                    9.15.2    Teva Pharmaceuticals Industries Limited in Nanopharmaceutical Drugs Market
                    9.15.3    Financials
                    9.15.4    Key Insights about Financial Health of the company
                    9.15.5    Global Presence
                    9.15.6    SWOT Analysis

10 Research Scope and Methodology

            10.1    Report Scope
            10.2    Global Nanopharmaceutical Drugs Market: Research Methodology

List of Tables

Table 1    Cancer Incidences (by Region), 2015
Table 2    Characterization Tools and Methods for Nanoparticles
Table 1.1    Various Characteristics and Brief Applications of Nanosystems
Table 1.2    Conventional Medicine vs. Nanomedicine
Table 2.1    Impact Analysis
Table 3.1    Drug Candidates in Different Phase of Development
Table 3.2    Nanopharmaceutical Drug Approvals
Table 4.1    Criterion for Patentability
Table 4.2    Selected Case Law Pertaining to Nanotechnology
Table 4.3    List of Regulatory Bodies across the World
Table 5.1    List of Liposome NPs
Table 5.2    List of Polymer NPs
Table 5.3    List of Nanocrystal NPs
Table 5.4    List of Inorganic NPs
Table 5.5    List of Protein NPs
Table 6.1    Currently Approved Nanomedicines in the Clinic (Cancer)
Table 8.1    North America Nanopharmaceutical Drugs Market (by Drug Carrier Type), 2017-2026, $B
Table 8.2    North America Nanopharmaceutical Drugs Market (by Application), 2017-2026, $Billion
Table 8.3    Europe Nanopharmaceutical Drugs Market (by Drug Carrier Type), 2017-2026
Table 8.4    Europe Nanopharmaceutical Drugs Market (by Application), 2017-2026
Table 8.5    Asia-Pacific Nanopharmaceutical Drugs Market(by Drug Carrier Type), 2017-2026
Table 8.6    Asia-Pacific Nanopharmaceutical Drugs Market, by Application, 2017-2026

List of Figures

Figure 1    Evolution of Nanomedicine
Figure 2    Global Nanopharmaceutical Drugs Market Share (by Drug Carrier Type), 2017
Figure 3    Global Nanopharmaceutical Drugs Market (by Drug Carrier Type), 2018 - 2026
Figure 4    Global Nanopharmaceutical Drugs Market (by Application), 2018 - 2026
Figure 5    Global Nanopharmaceutical Drugs Market (by Distribution Channel), 2018 - 2026
Figure 6    Global Nanopharmaceutical Drug Market, (by Region), 2017, 2021, and 2026
Figure 7    Global Nanopharmaceutical Drugs Market, 2017-2026
Figure 8    Global Nanopharmaceutical Drugs Market, 2017-2026, Y-o-Y
Figure 9    Nanomedicine Market: Impacting Factors
Figure 10    Global Nanopharmaceutical Drugs Market, Absolute Dollar Opportunity, Billion (by Region)
Figure 11    Global Nanopharmaceutical Drugs Market, Market Attractiveness (By Application)
Figure 1.1    Different Types of Biomarkers in Nanopharmaceutical Drug
Figure 1.2    Drug Particle Prepared in the Nanoscale Depends on Four Aspects of Nanopharmaceutical Lifestyle
Figure 1.3    Era of Nanodrug Delivery in Cancer
Figure 1.4    Introduction to Nanomedicine: Years of Commercialization
Figure 1.5    Concerns in Nanotech Product Development and its Commercialization
Figure 1.6    Impact of Market Drivers and Market Restraints
Figure 1.7    Global Nanopharmaceutical Drugs Market, 2017-2026
Figure 2.1    Market Dynamics
Figure 2.2    NNI Budget (by Agency), 2017–2019 (Proposed)
Figure 2.3    Number of ANDA Approvals, 2017
Figure 2.4    Nanotechnology Business
Figure 2.5    Pipeline Drugs: Clinical Opportunity
Figure 2.6    Pipeline Drugs: On Map
Figure 2.7    Nano based Drug Delivery Patent Filing, (By Region), 2015
Figure 2.8    Nanoparticles in Approved and Investigational Drugs, 2017
Figure 3.1    Market Potential, Drug Peak Sale ($Billion)
Figure 4.1    Industry Insights
Figure 4.2    Patent Expiration (By Drug Carrier Type), 2016
Figure 5.1    Types of  Nanocarriers
Figure 5.2    Global Nanopharmaceutical Drugs Market (by Drug Carrier Type), 2017 and 2026
Figure 5.3    Global Nanopharmaceutical Drugs Market (by Liposome Drug Carrier), 2017-2026
Figure 5.4    Global Nanopharmaceutical Drugs Market (by Polymer NP), 2017-2026
Figure 5.5    Global Nanopharmaceutical Drugs Market (by Nanocrystal Drug Carrier), 2017-2026
Figure 5.6    Global Nanopharmaceutical Drugs Market (by Inorganic), 2017-2026
Figure 5.7    Global Nanopharmaceutical Drugs Market (by Protein Drug Carrier), 2017-2026
Figure 5.8    Global Nanopharmaceutical Drugs Market (by Other Drug Carrier), 2017-2026
Figure 6.1    Global Nanopharmaceutical Drugs Market (by Application)
Figure 6.2    Global Nanopharmaceutical Drugs Market (by Products), 2017-2026
Figure 6.3    Global Nanopharmaceutical Drugs Market (by Oncology), 2017-2026
Figure 6.4    Nanomedicine in Neurology
Figure 6.5    Global Nanopharmaceutical Drugs Market (by Neurology), 2017-2026
Figure 6.6    Global Nanopharmaceutical Drugs Market (by Anti-inflammatory/Immunology), 2017-2026
Figure 6.7    Global Nanopharmaceutical Drugs Market (by Anti-infectives), 2017-2026
Figure 6.8    Global Nanopharmaceutical Drugs Market (by Cardiovascular and Physiology), 2017-2026
Figure 6.9    Global Nanopharmaceutical Drugs Market (by Other Application Areas), 2017-2026
Figure 7.1    Global Nanopharmaceutical Drugs Market (by Distribution Channel), 2017-2026
Figure 7.2    Global Nanopharmaceutical Drugs Market (by Hospital Pharmacy), 2017-2026
Figure 7.3    Global Nanopharmaceutical Drugs Market (by Retail and Drug Store), 2017-2026
Figure 7.4    Global Nanopharmaceutical Drugs Market (by Online Pharmacy), 2017-2026
Figure 8.1    Global Nanopharmaceutical Drugs Market Scenario, (CAGR), 2018-2026, (Market Value), (2017)
Figure 8.2    Global Nanopharmaceutical Drugs Market (by Region), 2017-2026
Figure 8.3    Global Nanopharmaceutical Drugs Market Share (by Region), 2017 and 2026
Figure 8.4    North America Nanopharmaceutical Drugs Market, (2017-2026)
Figure 8.5    North America Market Dynamics
Figure 8.6    North America Nanopharmaceutical Drugs Market (by Country), 2017-2026
Figure 8.7    The U.S Nanopharmaceutical Drugs Market, 2017-2026
Figure 8.8    Canada Nanopharmaceutical Drugs Market, 2017-2026
Figure 8.9    Europe Nanopharmaceutical Drugs Market, 2017-2026
Figure 8.10    Europe Market Dynamics
Figure 8.11    Europe Nanopharmaceutical Drugs Market (by Country), 2017-2026
Figure 8.12    Germany Nanopharmaceutical Drugs Market, 2017-2026
Figure 8.13    France Nanopharmaceutical Drugs Market, 2017-2026
Figure 8.14    The U.K. Nanopharmaceutical Drugs Market, 2017-2026
Figure 8.15    Spain Nanopharmaceutical Drugs Market, 2017-2026
Figure 8.16    Italy Nanopharmaceutical Drugs Market, 2017-2026
Figure 8.17    Rest-of-Europe Nanopharmaceutical Drugs Market, 2017-2026
Figure 8.18    Asia-Pacific Nanopharmaceutical Drugs Market, 2017-2026
Figure 8.19    Asia-Pacific Market Dynamics
Figure 8.20    Asia Pacific Nanopharmaceutical Drugs Market (by Country), 2017-2026
Figure 8.21    China Nanopharmaceutical Drugs Market, 2017-2026
Figure 8.22    Japan Nanopharmaceutical Drugs Market, 2017-2026
Figure 8.23    Rest-of-Asia Pacific Nanopharmaceutical Drugs Market, 2017-2026
Figure 8.24    Rest-of-the-World Nanopharmaceutical Drugs Market, (by Drug Carrier), 2017-2026
Figure 8.25    Rest-of-the-World Nanopharmaceutical Drugs Market, (by Application), 2017-2026
Figure 9.1    Abbvie Inc.: Product Offerings for Global Nanopharmaceutical Drugs Market
Figure 9.2    Abbvie Inc.: Overall Financials, 2015-2017
Figure 9.3    Abbvie Inc.: Revenue (by Region), 2015, 2016 and 2017
Figure 9.4    Abbvie Inc.: R&D Expense, 2015-2017
Figure 9.5    Abbvie Inc.: Revenue Forecast, 2015-2020
Figure 9.6    Abbvie Inc.: Global Presence
Figure 9.7    Abbvie Inc.: SWOT Analysis
Figure 9.8    AMAG Pharmaceuticals: Product Offerings for Global Nanopharmaceutical Drugs Market
Figure 9.9    AMAG Pharmaceuticals: Overall Financials, 2015-2017
Figure 9.10    AMAG Pharmaceuticals: Revenue (by Business Segment), 2015-2017
Figure 9.11    AMAG Pharmaceuticals: R&D Expense, 2015-2017
Figure 9.12    AMAG Pharmaceuticals: Revenue Forecast, 2015-2020
Figure 9.13    AMAG Pharmaceuticals: Global Presence
Figure 9.14    AMAG Pharmaceuticals: SWOT Analysis
Figure 9.15    Amgen, Inc.: Product Offerings for Global Nanopharmaceutical Drugs Market
Figure 9.16    Abbvie Inc.: Overall Financials, 2015-2017
Figure 9.17    Amgen Inc.: Revenue (by Region), 2015, 2016 and 2017
Figure 9.18    Amgen, Inc.: R&D Expense, 2015-2017
Figure 9.19    Amgen, Inc.: Revenue Forecast, 2015-2020
Figure 9.20    Amgen Inc.: Global Presence
Figure 9.21    Amgen, Inc.: SWOT Analysis
Figure 9.22    Astellas Pharma Inc.: Product Offerings for Global Nanopharmaceutical Drugs Market
Figure 9.23    Astellas Pharma Inc: Overall Financials, 2015-2017
Figure 9.24    Astellas Pharma Inc: Revenue (by Business Segment), 2016-2017
Figure 9.25    Astellas Pharma Inc.: Revenue (by Region), 2016-2017
Figure 9.26    Astellas Pharma Inc: R&D Expense, 2015-2017
Figure 9.27    AstraZeneca PLC: Revenue Forecast, 2015-2020
Figure 9.28    Astella Pharma Inc, SWOT Analysis
Figure 9.29    AstraZeneca PLC: Overall Financials, 2015-2017
Figure 9.30    AstraZeneca PLC: Revenue (by Region), 2015-2017
Figure 9.31    AstraZeneca PLC: R&D Expense, 2015-2017
Figure 9.32    AstraZeneca PLC: Global Presence
Figure 9.33    AstraZeneca PLC: SWOT Analysis
Figure 9.34    CELGENE CORPORATION: Product Offerings for Global Nanopharmaceutical Drugs Market
Figure 9.35    CELGENE CORPORATION: Overall Financials, 2015-2017
Figure 9.36    CELGENE CORPORATION: Revenue (by Region), 2015-2017
Figure 9.37    CELGENE CORPORATION: R&D Expense, 2015-2017
Figure 9.38    CELGENE CORPORATION: Revenue Forecast, 2015-2020
Figure 9.39    CELGENE CORPORATION: Global Presence
Figure 9.40    CELGENE CORPORATION: SWOT Analysis
Figure 9.41    Gilead Sciences, Inc: Product Offerings for Global Nanopharmaceutical Drugs Market
Figure 9.42    Gilead Sciences, Inc: Overall Financials, 2015-2017
Figure 9.43    Gilead Sciences, Inc: Revenue (by Region), 2015-2017
Figure 9.44    Gilead Sciences, Inc: R&D Expense, 2015-2017
Figure 9.45    Gilead Sciences, Inc: Revenue Forecast, 2015-2020
Figure 9.46    Gilead Sciences, Inc: Global Presence
Figure 9.47    Gilead Sciences, Inc: SWOT Analysis
Figure 9.48    Johnson & Johnson: Product Offerings for Global Nanopharmaceutical Drugs Market
Figure 9.49    Johnson & Johnson: Overall Financials, 2015-2017
Figure 9.50    Johnson & Johnson: Revenue (by Business Segment), 2015-2017
Figure 9.51    Johnson & Johnson: Revenue (by Region), 2015-2017
Figure 9.52    Johnson & Johnson: R&D Expense, 2015-2017
Figure 9.53    Johnson & Johnson: Revenue Forecast, 2015-2020
Figure 9.54    Johnson & Johnson: Global Presence
Figure 9.55    Johnson & Johnson: SWOT Analysis
Figure 9.56    Merck & Co., Inc.: Product Offerings for Global Nanopharmaceutical Drugs Market
Figure 9.57    Merck & Co., Inc.: Overall Financials, 2015-2017
Figure 9.58    Merck & Co., Inc.: Revenue (by Business Segment), 2015-2017
Figure 9.59    Merck & Co., Inc.: Revenue (by Region), 2015-2017
Figure 9.60    Merck & Co., Inc.: R&D Expense, 2015-2017
Figure 9.61    Merck & Co., Inc.: Revenue Forecast, 2015-2020
Figure 9.62    Merck & Co., Inc.: Global Presence
Figure 9.63    Merck & Co., Inc.: SWOT Analysis
Figure 9.64    Novartis AG: Product Offerings for Global Nanopharmaceutical Drugs Market
Figure 9.65    Novartis AG: Overall Financials, 2015-2017
Figure 9.66    Novartis AG: Revenue (by Business Segment), 2015-2017
Figure 9.67    Novartis AG: Revenue (by Region), 2015-2017
Figure 9.68    Novartis AG: R&D Expense, 2015-2017
Figure 9.69    Novartis AG: Revenue Forecast, 2015-2020
Figure 9.70    Novartis AG: Global Presence
Figure 9.71    Novartis AG: SWOT Analysis
Figure 9.72    Pfizer, Inc.: Product Offerings for Global Nanopharmaceutical Drugs Market
Figure 9.73    Pfizer, Inc.: Overall Financials, 2015-2017
Figure 9.74    Pfizer, Inc.: Revenue (by Business Segment), 2015, 2016 and 2017
Figure 9.75    Pfizer, Inc.: Revenue (by Region), 2015, 2016 and 2017
Figure 9.76    Pfizer, Inc.: R&D Expense, 2015-2017
Figure 9.77    Pfizer, Inc.: Revenue Forecast, 2015-2020
Figure 9.78    Pfizer, Inc.: Global Presence
Figure 9.79    Pfizer, Inc.: SWOT Analysis
Figure 9.80    F. Hoffmann-La Roche AG: Product Offerings for Global Nanopharmaceutical Drugs Market
Figure 9.81    F. Hoffmann-La Roche AG: Overall Financials, 2015-2017
Figure 9.82    F. Hoffmann-La Roche AG: Revenue (by Business Segment), 2015-2017
Figure 9.83    F. Hoffmann-La Roche AG: Revenue (by Region), 2015-2017
Figure 9.84    F. Hoffmann-La Roche AG: R&D Expense, 2015-2017
Figure 9.85    F. Hoffmann-La Roche AG: Revenue Forecast, 2015-2020
Figure 9.86    F. Hoffmann-La Roche AG: Global Presence
Figure 9.87    F. Hoffmann-La Roche AG: SWOT Analysis
Figure 9.88    Sanofi S.A.: Product Offerings for Global Nanopharmaceutical Drugs Market
Figure 9.89    Sanofi S.A: Overall Financials, 2015-2017
Figure 9.90    Sanofi S.A: Revenue (by Business Segment), 2015-2017
Figure 9.91    Sanofi S.A: Revenue (by Region), 2015-2017
Figure 9.92    Sanofi S.A: R&D Expense, 2015-2017
Figure 9.93    Sanofi S.A: Revenue Forecast, 2015-2020
Figure 9.94    Sanofi S.A: Global Presence
Figure 9.95    Sanofi S.A: SWOT Analysis
Figure 9.96    Shire plc.: Product Offerings for Global Nanopharmaceutical Drugs Market
Figure 9.97    Shire plc.: Overall Financials, 2015-2017
Figure 9.98    Shire PLC: Revenue (by Business Segment), 2015-2017
Figure 9.99    Shire PLC: R&D Expense, 2015-2017
Figure 9.100    Shire PLC: Revenue Forecast, 2015-2020
Figure 9.101    Shire PLC: Global Presence
Figure 9.102    Shire PLC: SWOT Analysis
Figure 9.103    Teva Pharmaceuticals Industries Limited: Product Offerings for Global Nanopharmaceutical Drugs Market
Figure 9.104    Teva Pharmaceuticals Industries Limited: Overall Financials, 2015-2017
Figure 9.105    Teva Pharmaceuticals Industries Limited: Revenue (by Business Segment), 2015-2017
Figure 9.106    Teva Pharmaceuticals Industries Limited: Revenue (by Region), 2015-2017
Figure 9.107    Teva Pharmaceuticals Industries Limited: R&D Expense, 2015-2017
Figure 9.108    Teva Pharmaceuticals Industries Limited: Revenue Forecast, 2015-2020
Figure 9.109    Teva Pharmaceuticals Industries Limited: Global Presence
Figure 9.110    Teva Pharmaceuticals Industries Limited: SWOT Analysis
Figure 10.1    Global Nanopharmaceutical Drugs Market Scope
Figure 10.2    Global Nanopharmaceutical Drugs Market: Research Methodology
Figure 10.3    Primary Research
Figure 10.4    Secondary Research
Figure 10.5    Data Triangulation
Figure 10.6    Top-down Approach (Segment-wise Analysis)
Figure 10.7    Bottom-up Approach (Segment-wise Analysis)
Figure 10.8    Assumptions and Limitations
Figure 10.9    Considered Factors for Data Prediction and Modelling

You may also like

Published Year: 2018

Global Injectable Drug Delivery Market : Focus on Devices, Competitive Landscape and Country - Analy

The global injectable drug delivery market was estimated at $16.73 billion in 2016 and is...

 
Published Year: 2018

Global Drug Infusion Systems Market: Focus on Products, Application, Competitive Landscape and 57 Co

The global drug infusion systems market was estimated to be $8.1 billion in 2016 and is...

 

Global Nanopharmaceutical Drugs Market - Analysis and Forecast (2018-2026)

Focus on Nanodrugs and its Application in Therapeutics, Competitive Landscape, and Country